Nicardipine: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "0 mg" to "0mg") |
Elcatracho (talk | contribs) |
||
(7 intermediate revisions by 5 users not shown) | |||
Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: [[Calcium Channel Blocker]] | *Type: [[Calcium Channel Blocker]], dihydropyridine | ||
*Dosage Forms: Capsule, Infusion solution, Injectable solution | *Dosage Forms: Capsule, Infusion solution, Injectable solution | ||
*Common Trade Names: [[Cardene]] | *Common Trade Names: [[Cardene]] | ||
Line 7: | Line 7: | ||
===[[Hypertension]]=== | ===[[Hypertension]]=== | ||
*PO: 20-40mg q8hr, or 30-60mg (extended release) q12hr | *PO: 20-40mg q8hr, or 30-60mg (extended release) q12hr | ||
*IV: 5mg/hr by slow infusion ( | *IV: 5mg/hr by slow infusion (50ml/hr), titrate to maximum of 30mg/hr, then maintenance of 2.0 - 15.5mg/hr | ||
*IV bolus dose of 2mg, then continuous infusion achieves same control of | *IV bolus dose of 2mg, then continuous infusion achieves same control of hypertension as starting infusion without bolus<ref>Tao P, Zheng DY, Yu XJ. Effects of intravenous nicardipine in Chinese patients with hypertensive emergencies. Curr Ther Res Clin Exp 1998 Mar; 59: 188-95.</ref> | ||
===[[Intracranial hemorrhage]]=== | |||
*Start at 5mg/hr | |||
**Increase q5min by 2.5mg until the target blood pressure is achieved | |||
**Then, immediately titrate down to maintenance infusion of 3mg/hr | |||
===Chronic [[Stable Angina]]=== | ===Chronic [[Stable Angina]]=== | ||
Line 24: | Line 29: | ||
*Renal Dosing | *Renal Dosing | ||
**Adult | **Adult | ||
*** PO: 20 mg TID (immediate release) or 30 mg BID (sustained release) with slow titration | |||
*** IV: not defined, slow titration | |||
**Pediatric | **Pediatric | ||
*** IV: not defined, slow titration | |||
*Hepatic Dosing | *Hepatic Dosing | ||
**Adult | **Adult | ||
*** PO: 20 mg BID (immediate release) with slow titration | |||
*** IV: not defined, slow titration | |||
**Pediatric | **Pediatric | ||
*** IV: not defined, slow titration | |||
==Contraindications== | ==Contraindications== | ||
Line 51: | Line 62: | ||
==See Also== | ==See Also== | ||
*[[Subarachnoid hemorrhage]] | |||
*[[Hemorrhagic stroke]] | |||
*[[Hypertensive emergency]] | |||
*[[Clevidipine]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Cardiology]] | |||
Nicardipine: Drug information. UpToDate. www.uptodate.com. Accessed April 2, 2019. |
Revision as of 03:51, 6 March 2021
General
- Type: Calcium Channel Blocker, dihydropyridine
- Dosage Forms: Capsule, Infusion solution, Injectable solution
- Common Trade Names: Cardene
Adult Dosing
Hypertension
- PO: 20-40mg q8hr, or 30-60mg (extended release) q12hr
- IV: 5mg/hr by slow infusion (50ml/hr), titrate to maximum of 30mg/hr, then maintenance of 2.0 - 15.5mg/hr
- IV bolus dose of 2mg, then continuous infusion achieves same control of hypertension as starting infusion without bolus[1]
Intracranial hemorrhage
- Start at 5mg/hr
- Increase q5min by 2.5mg until the target blood pressure is achieved
- Then, immediately titrate down to maintenance infusion of 3mg/hr
Chronic Stable Angina
- 20-40mg PO q8hr
- Allow 3 days between dose increase
Pediatric Dosing
Hypertension
- 0.5-3 mcg/kg/min IV
- Not approved by FDA; limited date available
Special Populations
- Pregnancy Rating: Category C
- Lactation: Unknown wether drug is excreted in breast milk; avoid use
- Renal Dosing
- Adult
- PO: 20 mg TID (immediate release) or 30 mg BID (sustained release) with slow titration
- IV: not defined, slow titration
- Pediatric
- IV: not defined, slow titration
- Adult
- Hepatic Dosing
- Adult
- PO: 20 mg BID (immediate release) with slow titration
- IV: not defined, slow titration
- Pediatric
- IV: not defined, slow titration
- Adult
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Headache (IV, 15%)
Common
- Flushing
- Peripheral Edema
- Pedal Edema
- Hypotension
- Exacerbation of angina
Pharmacology
- Half-life: 2-4 hr
- Metabolism: Metabolized in liver b CYP3A4 (first pass)
- Excretion: urine (60%), feces (35%)
- Mechanism of Action:
- inhibits trasmembrane influx of extracellular calcium ions across membranes of myocardial cells and vascular smooth muscle cells without changing serum calcium concentrations; this inhibit cardiac and vascular smooth muscle contractions, thereby dilating maincoronary and systemic arteries.
See Also
References
- ↑ Tao P, Zheng DY, Yu XJ. Effects of intravenous nicardipine in Chinese patients with hypertensive emergencies. Curr Ther Res Clin Exp 1998 Mar; 59: 188-95.
Nicardipine: Drug information. UpToDate. www.uptodate.com. Accessed April 2, 2019.